Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) announced on October 30, 2026, that it has reached an agreement with certain creditors to settle up to $500,000 in outstanding accounts payable through the issuance of up to 5,000,000 common shares. The settlement shares will be priced at $0.10 each, in line with Canadian Securities Exchange policies. The transaction is designed to improve the Burlington, Ontario-based biotechnology company's financial position by reducing its existing liabilities.

Key Points

  • Rapid Dose Therapeutics Corp. (CSE: DOSE, OTCQB: RDTCF) is a Canadian biotechnology company based in Burlington, Ontario
  • The company has agreed to issue up to 5,000,000 common shares at $0.10 per share to settle up to $500,000 in outstanding accounts payable
  • Settlement shares issued to Canadian residents will be subject to a four-month hold period from the date of issuance
  • Investors should watch for CSE acceptance of the transaction, which remains a condition for completion

Structure of the Rapid Dose Shares-for-Debt Transaction

Under the proposed arrangement, Rapid Dose Therapeutics will issue up to 5,000,000 common shares — referred to as Settlement Shares — to participating creditors in exchange for the cancellation of accounts payable totalling up to $500,000. The issuance price of $0.10 per share was set in accordance with CSE policies. The company states that no new control person will be created as a result of the transaction, meaning existing governance and ownership thresholds are not expected to be materially affected by the debt settlement.

Resale Restrictions on Settlement Shares for Canadian Residents

Creditors who are Canadian residents and receive Settlement Shares will face a four-month hold period from the date of issuance, restricting their ability to trade the shares in the near term. This restriction is consistent with standard Canadian securities regulations governing shares issued without a prospectus. The transaction remains subject to acceptance by the CSE, and the company has not disclosed a specific timeline for when that regulatory approval is anticipated or when the shares will formally be issued to creditors.

QuickStrip™ Technology Underpins Rapid Dose's Business Model

Rapid Dose Therapeutics describes itself as a Canadian biotechnology company focused on drug delivery innovation. Its flagship product, QuickStrip™, is a thin, orally dissolvable film designed to deliver active ingredients — including nutraceuticals, pharmaceuticals, and vaccines — rapidly into the bloodstream. The company states the film can be infused with a broad range of active ingredients. Investors may be watching how the debt reduction effort positions the company to advance its QuickStrip™ platform commercially, though no operational guidance was provided in this announcement.